Noopur Raje, MD, on Current CAR T Options in Multiple Myeloma
The director of the Center for Multiple Myeloma at Mass Gen discussed current CAR T-cell therapies in multiple myeloma.
This content originally appeared on our sister site, OncLive.
Chimeric antigen receptor (CAR) T-cell therapies are a growing option for the treatment of multiple myeloma. Idecabtagene vicleucel (ide-cel; Abecma) was approeved in March 2021 for the treatment of patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy. Ciltacabtagene autoleucel (cilta-cel; Carvykti) was apprpved in February 2022 for the treatment of adult patients with relapsed/refractory multiple myeloma following 4 or more prior lines of therapy.
Patients eligible for CAR T-cell therapy treatment have highly refractory disease and have been exposed to a majority of treatment options, including lenalidomide (Revlimid), pomalidomide (Pomalyst), bortezomib (Velcade), carfilzomib (Kyprolis), and an anti-CD38 monoclonal antibody.
OncLive spoke with Noopur Raje, MD, to learn more about the current CAR T-cell therapy options available for patients with relapsed/refractory multiple myeloma.
